Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
izalontamab brengitecan + axitinib
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
**Izalontamab brengitecan + axitinib** is an investigational combination therapy for advanced solid tumors, particularly non-small cell lung cancer (NSCLC). Izalontamab brengitecan (BL-B01D1, also known as iza-bren) is a first-in-class bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, conjugated to a novel topoisomerase I inhibitor payload through a tetrapeptide cleavable linker. Axitinib is a small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3). The combination aims to inhibit tumor growth by targeting receptor-mediated growth signaling and tumor angiogenesis.
- Brand names
- izalontamab brengitecan + axitinib
- Other names
- izalontamab brengitecan + axitinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)TOP1 (DNA Topoisomerase I)EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on izalontamab brengitecan + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on izalontamab brengitecan + axitinib.